When your investment case breaks down, why not just do the decent thing?
ApexOnco Front Page
Recent articles
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
The players are vying in the CD19 x CD20 Car-T arena.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
But the former is paying a fraction of what Merck shelled out for raludotatug.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
